Neurent Medical has closed an oversubscribed Series C financing round, raising €62.5m ($74m) to expand commercial activities for the NEUROMARK system targeting chronic rhinitis, generate additional clinical evidence, and further develop its product and indication pipeline.

MVM Partners led the financing with participation from Sofinnova Partners, alongside continued support from Atlantic Bridge, EQT Life Sciences, Enterprise Ireland, and Fountain Healthcare Partners.

Chronic rhinitis is a condition affecting millions worldwide, marked by ongoing symptoms such as rhinorrhoea, nasal congestion, postnasal drip, and sneezing.

NEUROMARK uses Impedance Controlled Radiofrequency technology to target overactive posterior nasal nerves (PNN), aiming to address the underlying cause rather than only managing symptoms.

The company has also added MVM partner Kyle Dempsey and Sofinnova partner Cedric Moreau to its board of directors.

Neurent Medical CEO Brian Shields said: “I am delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team, two global leaders in medtech investing. This Series C financing will support our commercial expansion and help bring NEUROMARK to the patients and physicians who need it most.”

Dempsey said: “Millions of patients suffer from chronic rhinitis, and posterior nasal nerve ablation represents a powerful tool to provide proven relief. In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure.”

The company is headquartered in Galway, Ireland and has operations in Braintree, Massachusetts, US.

In June 2025, the US Food and Drug Administration (FDA) granted 510(k) clearance to the NEUROMARK system to treat individuals with chronic rhinitis.